美国急性呼吸窘迫综合征 (ARDS) 市场 – 行业趋势和 2029 年预测

美国急性呼吸窘迫综合征 (ARDS) 市场分析和见解

美国急性呼吸窘迫综合征 (ARDS) 市场预计将在 2022 年至 2029 年的预测期内显着增长。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，该市场以 10.6% 的复合年增长率增长，预计到 2029 年将达到 70.8346 亿美元。推动市场增长的主要因素是急性肺损伤的患病率和发病率的增加、ARDS 的多种风险因素和患有 ARDS 的 covid-19 患者群的加速增加、空气污染和生活方式相关疾病的发生率上升、以及导致 ARDS 的事故率和创伤的增加。

急性呼吸窘迫综合征 (ARDS) 是一种危及生命的肺部损伤，会导致液体渗入肺部。大多数患有 ARDS 的人已经因创伤或 COVID-19 等疾病住院。这种综合征通常发生在肺部微小的弹性气囊（称为肺泡）中积聚液体时。这种液体积聚会导致血液中的氧气减少。这使器官无法获得足够的氧气来维持正常功能。患有其他疾病的人在诱发损伤或感染后的几小时到几天内会患上 ARDS。死亡风险随着年龄的增长而增加，并且根据疾病的严重程度，患者很难从该综合征中幸存下来。严重的疾病或损伤导致肺膜囊受损，从而导致 ARDS。上述疾病最常见的潜在原因包括败血症、吸入有害物质、严重肺炎、头部、胸部或其他重大损伤、2019 年冠状病毒病 (COVID-19) 等。

美国急性呼吸窘迫综合征 (ARDS) 市场报告提供了市场份额、新发展以及国内和本地市场参与者的影响的详细信息，分析了新兴收入来源、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情景，请联系我们获取分析师简报。我们的团队将帮助您创建收入影响解决方案，以实现您的期望目标。

Market Definition

The increasing prevalence and incidence of acute lung injury is an important driver for the U.S. acute respiratory distress syndrome (ARDS) market. A wide range of risk factors for ARDS and acceleration in a patient pool of covid-19 with ARDS accelerate market growth. The major restraints may negatively impact the U.S. acute respiratory distress syndrome (ARDS) market. Complications associated with treatments and high cost of device and treatments. The growing geriatric population is expected to provide market opportunities. However, stringent rules and regulations are projected to challenge U.S. acute respiratory distress syndrome (ARDS) market growth.

U.S. Acute Respiratory Distress Syndrome (ARDS) Market Dynamics

Drivers

• Increasing prevalence and incidence of acute lung injury

Patients with acute lung injuries are being widely reported due to numerous factors like the increasing aged population and the rising number of patients with sepsis and pneumonia, among others. However, most people get diagnosed with lung injuries and acute respiratory distress syndrome only at the late stages. Thereby, the incidence and prevalence of ARDS keep increasing, and the disease has been widely recognized as a major clinical problem worldwide, carrying high morbidity and mortality burden. Hence, increasing prevalence and incidence rates of acute lung injuries and accompanied acute respiratory distress syndrome drive the U.S. acute respiratory distress syndrome (ARDS) market.

• Wide range of risk factors for ARDS

An enormous range of risk factors is reported for acute respiratory distress syndrome. There are environmental and individual risk factors involved with the syndrome. Some chronic alcohol consumption and active or passive cigarette smoking have been commonly associated. Hence, increasing alcohol consumption irrespective of age leads to syndrome-like ARDS. Other risk factors like dyspnoea, hypertension, diabetes, and more lead to ARDS development. Thereby, this wide range of risk factors associated with acute respiratory distress syndrome increases the possibility of developing the clinical condition, simultaneously raising the cases of the disease. These affirmative risk factors are anticipated to boost the growth of the market.

• Acceleration in patient pool of covid-19 with Acute Respiratory Distress Syndrome (ARDS)

As the world is suffering enormously from COVID-19 infection, there is also a direct correlation between COVID-19 and acute respiratory distress syndrome. Severe cases of COVID-19 disease will ultimately lead to ARDS and pneumonia. This has been proven to be fatal for infected individuals. When the COVID-19-causing virus enters the body, it attaches to the upper airway cells. This sets off an immune response that causes inflammation and leads to symptoms such as cough, sore throat, and fever. In some severe cases, the virus travels beyond the upper airway, moves through the lungs, and ends up in the alveoli. Thereby, the rising number of COVID-19 cases also increases the chance of acute respiratory distress syndrome among people, which is expected to act as a driver for the growth of the acute respiratory distress syndrome market.

• The rising rate of air pollution and lifestyle-related diseases

Long-term exposure to low to moderate air pollution is associated with a greater risk factor for developing any lung infection, including ARDS. This is a novel and potentially modifiable environmental risk factor for acute respiratory distress syndrome. According to the World Health Organization, air pollution is one of the greatest environmental risks to health by increasing the burden of diseases like heart diseases and lung and respiratory infections at both acute and chronic levels. Hence, the rising air pollution rate in developed and developing countries increases the chances of people getting syndromes like acute respiratory distress syndrome. Thus, the factor is expected to drive the growth of the market.

• Increasing accident rates and trauma causing Acute Respiratory Distress Syndrome (ARDS)

Major trauma caused by accidents is a well-known risk factor for the development of ARDS. Acute respiratory distress syndrome can result from an injury to the body by creating inflammation of the pancreas, breathing contents of the stomach into the lung, blood transfusions, house fire and smoke inhalation, serious infection, drowning trauma, and severe reaction to medications. Even car accidents are a cause of ARDS. Hence, inhalation of smoke releases certain materials like fibrin, neutrophils, mucus, and epithelial cell debris that occlude the airway lumen, causing changes in ventilation. This condition leads to hypoxemia which is a primary significant reason for ARDS.

Opportunities

• Growing geriatric population

The 'world's geriatric population is increasing at a rapid rate. Older people have become an increasingly prevalent population of intensive care admissions. As per an article on National Center for Biotechnology Information (NCBI), the mortality rate associated with acute respiratory distress syndrome (ARDS) has been 69% to 80% reported among the elderly population, making it riskier for geriatric people. Thus, the growing pace of the older population demonstrates the escalation in demand for acute respiratory distress syndrome treatments as they are more vulnerable to severe respiratory illness due to their weak immune system. It is anticipated that the -increasing geriatric population, which is expected to rise in future years worldwide, creates an opportunity for market growth in the forecast period.

• Rising healthcare expenditure

Healthcare expenditure has increased worldwide as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, the government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for acute respiratory distress syndrome, as the disorder has been highly prevalent in recent years. Growing healthcare expenditure is also beneficial for further economic and healthcare sector growth. It is primarily fruitful as it significantly affects the development of better and advanced therapeutic options with ventilators and other ARDS treatment devices.

• Strategic initiatives by market players

With increasing rates of infectious diseases such as COVID-19 and chronic diseases like lung cancer, the simultaneous burden of 'syndrome like ARDS is widely seen globally. The dramatic rise in research quality and increasing research opportunities is because of various strategic initiatives these players take. They are taking initiatives such as product launches, collaborations, mergers, acquisitions, and many more over the years and are expected to lead and create more opportunities in the market. These strategic product launches, acquisitions, and mergers done by major companies in the acute respiratory distress syndrome market have opened up opportunities for companies in various regions. This strategy is allowing the companies to strengthen their footprints in the market.

• Improving awareness regarding Acute Respiratory Distress Syndrome (ARDS)

Since acute respiratory distress syndrome has multiple different causes, it is usually ignored under common causes of death. The requirement of advanced technical treatment and proper awareness of the condition can substantially decline ARDS incidence. As timely diagnosis and prevention are crucial to preventing or recovering faster, the public's attention is most important. Current government and organizations have broadened the scope of lung injury research to include primary prevention of ARDS and reduce the morbidity or mortality rate for the syndrome. Thereby, increasing awareness regarding ARDS by diverse 'association's support enhances the U.S. acute respiratory distress syndrome 'market's opportunity for wide growth in the future.

Restraints/Challenges

• Complications associated with treatments

Acute respiratory distress syndrome is a clinical condition requiring proper and timely treatment and cares to prevent mortality and morbidity rates. However, during the treatment of ARDS, the patients might face many complications in the hospitals. Though there are treatments for ARDS helping people survive, the complications associated during treatments and post-treatment are still a burden for patients. Most potential and lasting effects include breathing problems, depression, problems with memory and thinking, tiredness and muscle weakness, and more. These complications associated with and post-treatment of acute respiratory distress syndrome are expected to hamper the market growth during our forecast period.

• High cost of device and treatments

Though acute respiratory distress syndrome is getting a wide range of advanced treatment options, the cost of treatment for longer is quite difficult for average-income people to afford. The utilization of critical care and intensive care unit services is increasing worldwide, and its expensive cost is a major concern in the current healthcare system. Patients with ARDS are commonly required to have long hospitalizations with frequent monetarization and ventilation usage, consuming a significant amount of healthcare resources. Therefore, the high cost of treatment and ventilators is very challenging for people to afford any reliable remedy for the long term until the patient completely recovers. This is anticipated to hamper the growth of the market.

• Lack of skilled workforce

The sudden COVID-19 crisis has created various challenges to be faced by a healthcare organization, including a workforce shortage. The pandemic massively struck developed countries like the U.S. They initiated multiple ways to overcome such challenges, but news articles reported that the countries were dealing with staffing shortages. There were shortages of nurses even before the pandemic began in the U.S., as the region has a high population with respiratory disorders. Therefore, the lack of appropriately skilled and trained nurses in the ICU will be a more remarkable restraint expected to hamper the growth of the acute respiratory distress syndrome (ARDS) market.

• Stringent rules & regulations

The use of ventilators across the globe is rapidly increasing, with the growth of the aged population and several acute lung diseases, including acute respiratory distress syndrome, which is preventable by early diagnosis and timely treatments. At the same time, the players of the acute respiratory distress syndrome manufacturers in the market have to follow specific regulations to get approval from the upper authorities to launch the product like mechanical ventilators or humidifiers. These stringent guidelines need to be followed, and this is one of the most difficult tasks among all the steps. For example, the U.S. Food and Drug Administration (FDA) regulates respiratory ailment products in the U.S. Therefore, the stringent rules & regulations for product approval challenge the market's growth.

• Multiple challenges faced by ICU nurses

由于患者人数众多，医院资源匮乏，重症监护病房在疫情期间面临诸多挑战。自第一波 COVID-19 疫情爆发以来，医院增加了 ICU 的容量和潜力，导致 ICU 医护人员的工作时间增加。由于处理感染患者的原因多种多样，ICU 的护士总是心存恐惧。因此，最大的挑战是护士和其他医护人员在处理急性呼吸窘迫综合征和严重急性呼吸综合征时面临的困难。组织正在尝试用新的创新理念和任命更多的员工来克服这些困难。

近期发展

• 2020 年 7 月，吉利德科学公司启动了瑞德西韦吸入溶液的临床试验，用于治疗 COVID-19 的潜在门诊治疗。这项测试帮助该公司增强了其抗病毒产品组合，从而巩固了其在市场上的影响力

美国急性呼吸窘迫综合征 (ARDS) 市场范围

美国急性呼吸窘迫综合征 (ARDS) 市场根据病因、类型、给药途径、最终用户和分销渠道进行分类。这些细分市场之间的增长将帮助您分析行业中的主要增长细分市场，并为用户提供有价值的市场概览和市场洞察，以便做出战略决策，确定核心市场应用。

原因

• 2019 冠状病毒病 (COVID-19)
• 脓毒症
• 吸入有害物质
• 严重肺炎
• 其他的

根据病因，美国急性呼吸窘迫综合征 (ARDS) 市场分为 2019 年冠状病毒病 (COVID-19)、败血症、吸入有害物质、严重肺炎等。

类型

• 诊断
• 治疗

根据类型，美国急性呼吸窘迫综合征 (ARDS) 市场分为诊断和治疗。

给药途径

• 口服
• 肠外
• 其他的

根据给药途径，美国急性呼吸窘迫综合征 (ARDS) 市场分为口服、肠外和其他。

最终用户

• 医院
• 专科诊所
• 家庭医疗保健
• 其他的

根据最终用户，美国急性呼吸窘迫综合征 (ARDS) 市场分为医院、专科诊所、家庭医疗保健和其他。

分销渠道

• 直接招标
• 医院药房
• 零售药店
• 网上药店
• 其他的

根据分销渠道，美国急性呼吸窘迫综合征 (ARDS) 市场分为直接招标、医院药房、零售药房、网上药房和其他。

竞争格局和美国急性呼吸窘迫综合征 (ARDS) 市场份额分析

美国急性呼吸窘迫综合征 (ARDS) 市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用主导地位、技术生命线曲线。以上提供的数据点仅与公司对美国急性呼吸窘迫综合征 (ARDS) 市场的关注有关。

在美国急性呼吸窘迫综合征 (ARDS) 市场运营的一些知名参与者包括 Gilead Sciences, Inc.、Terumo Medical Corporation、Getinge AB.、Medtronic、LivaNova PLC、Fresenius SE & Co. KGaA、Drägerwerk AG & Co. KGaA、F. Hoffmann-La Roche Ltd、Fisher & Paykel Healthcare Limited.、Hamilton Medical、NIPRO、Pfizer Inc.、ResMed、Smiths Medical、WEINMANN Emergency Medical Technology GmbH + Co. KG。

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、美国与地区以及供应商份额分析。如有进一步询问，请要求分析师致电。

SKU-67938